Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome
- PMID: 28832484
- DOI: 10.1097/AOG.0000000000002296
Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome
Abstract
Hereditary breast and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by multiple family members with breast cancer, ovarian cancer, or both. Based on the contemporary understanding of the origins and management of ovarian cancer and for simplicity in this document, ovarian cancer also refers to fallopian tube cancer and primary peritoneal cancer. Clinical genetic testing for gene mutations allows more precise identification of those women who are at an increased risk of inherited breast cancer and ovarian cancer. For these individuals, screening and prevention strategies can be instituted to reduce their risks. Obstetrician-gynecologists play an important role in the identification and management of women with hereditary breast and ovarian cancer syndrome. If an obstetrician-gynecologist or other gynecologic care provider does not have the necessary knowledge or expertise in cancer genetics to counsel a patient appropriately, referral to a genetic counselor, gynecologic or medical oncologist, or other genetics specialist should be considered (1). More genes are being discovered that impart varying risks of breast cancer, ovarian cancer, and other types of cancer, and new technologies are being developed for genetic testing. This Practice Bulletin focuses on the primary genetic mutations associated with hereditary breast and ovarian cancer syndrome, BRCA1 and BRCA2, but also will briefly discuss some of the other genes that have been implicated.
Similar articles
-
Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome.Obstet Gynecol. 2017 Sep;130(3):657-659. doi: 10.1097/AOG.0000000000002285. Obstet Gynecol. 2017. PMID: 28832475
-
ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome.Obstet Gynecol. 2009 Apr;113(4):957-966. doi: 10.1097/AOG.0b013e3181a106d4. Obstet Gynecol. 2009. PMID: 19305347
-
Hereditary breast-ovarian cancer: clinical findings and medical management.Plast Surg Nurs. 2007 Jul-Sep;27(3):124-7. doi: 10.1097/01.PSN.0000290280.48197.e7. Plast Surg Nurs. 2007. PMID: 17901820 Review.
-
Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION SUMMARY, Number 793.Obstet Gynecol. 2019 Dec;134(6):1366-1367. doi: 10.1097/AOG.0000000000003563. Obstet Gynecol. 2019. PMID: 31764755
-
Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION, Number 793.Obstet Gynecol. 2019 Dec;134(6):e143-e149. doi: 10.1097/AOG.0000000000003562. Obstet Gynecol. 2019. PMID: 31764758
Cited by
-
Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with BRCA1/2 Pathogenic Variants: A Population-Based Retrospective Cohort Study.Curr Oncol. 2023 Oct 22;30(10):9367-9381. doi: 10.3390/curroncol30100678. Curr Oncol. 2023. PMID: 37887578 Free PMC article.
-
Attitude of BRCA1/2 mutation carriers towards fertility preservation, family planning and preimplantation genetic testing for primary prevention of breast and ovarian cancer in the next generation.J Assist Reprod Genet. 2023 Dec;40(12):2835-2842. doi: 10.1007/s10815-023-02954-1. Epub 2023 Sep 26. J Assist Reprod Genet. 2023. PMID: 37751121
-
Comprehensive clinical characterization of patients with BRCA1: c.5017_5019del germline variant.Ann Surg Treat Res. 2022 Dec;103(6):323-330. doi: 10.4174/astr.2022.103.6.323. Epub 2022 Dec 8. Ann Surg Treat Res. 2022. PMID: 36601340 Free PMC article.
-
Risk-Reducing Salpingo-Oophorectomy (RRSO) Combined with Simultaneous Mastectomy in Women with BRCA 1-2 Mutation Carriers: The Surgical Technique, the Feasibility and Patients' Satisfaction of Multiple Surgeries.J Clin Med. 2022 Dec 18;11(24):7502. doi: 10.3390/jcm11247502. J Clin Med. 2022. PMID: 36556118 Free PMC article.
-
Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience.Diagnostics (Basel). 2022 Dec 6;12(12):3054. doi: 10.3390/diagnostics12123054. Diagnostics (Basel). 2022. PMID: 36553061 Free PMC article.
References
-
- Counseling about genetic testing and communication of genetic test results. Committee Opinion No. 693. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;129:e96–101. (Level III)
-
- Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700–10. (Level II-3)
-
- Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807–16. (Level II-3)
-
- Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011;108:18032–7. (Level III)
-
- Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014;20:764–75. (Level II-2)
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
